Clinical Report: Modulating the histamine H4 receptor enhances anti-tumor efficacy

Overview

This study demonstrates that blockade of the histamine H4 receptor (H4R) using the antagonist JNJ777120 significantly inhibits tumor progression in a murine model of breast cancer. The findings suggest that H4R modulation enhances anti-tumor immune responses, particularly through the recruitment of CD8+ T cells.

Background

Breast cancer remains a leading cause of cancer-related mortality among women globally. The histamine H4 receptor has been implicated in tumor progression and immune modulation, making it a potential target for therapeutic intervention. Understanding the dual role of histamine in cancer could lead to novel treatment strategies, particularly for aggressive subtypes like triple-negative breast cancer.

Data Highlights

No numerical data available in the source material.

Key Findings

• Blockade of H4R with JNJ777120 inhibits tumor cell proliferation and migration.
• JNJ treatment increases CD8+ T cell recruitment and lymphocyte proliferation in tumors.
• The anti-tumor effect of H4R blockade is absent in adaptive immune-deficient Rag1 mice.
• Altered energy metabolism is observed in tumor-derived cells following H4R blockade.
• Histamine's role in breast cancer is context-dependent, influenced by tumor microenvironment factors.

Clinical Implications

The findings suggest that targeting the histamine H4 receptor may enhance anti-tumor immune responses in breast cancer, particularly in aggressive subtypes. Clinicians may consider exploring H4R antagonists as a potential adjunct therapy in breast cancer treatment regimens.

Conclusion

Modulating the histamine H4 receptor presents a promising strategy to improve anti-tumor efficacy in breast cancer, warranting further investigation in clinical settings.

References

1. Nicoud MB et al., Frontiers in Immunology, 2026 -- Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer
2. The ASCO Post, 2011 -- Novel HDAC Inhibitor May Restore Estrogen Sensitivity in Breast Cancer Related Articles
3. Springer, 2014 -- Suppression of Gastric Cancer Development In Vivo through Inhibition of β-catenin and STAT3 by a Curcumin Derivative
4. The ASCO Post, 2018 -- HDAC Inhibitor May Overcome Endocrine Resistance in Advanced Breast Cancer
5. New England Journal of Medicine, 2026 -- New England Journal of Medicine Publishes Phase 3 ASCENT 04/KEYNOTE D19 Results Supporting Trodelvy® Plus Keytruda®
6. Brain — Inhibition of CCL2 Alongside PD-1 and P-Selectin Immunomodulators Reduces Brain Metastasis in Breast Cancer
7. New England Journal of Medicine Publishes Phase 3 ASCENT 04/KEYNOTE D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First line PD L1+ Metastatic Triple negative Breast Cancer
8. Frontiers | Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer